Search results
COVID-19 is surging. Time to mask up or get a booster? What a Boise medical expert says
Idaho Statesman McClatchy via AOL· 4 days agoThe Centers for Disease Control and Prevention recommends everyone 6 months and older get an updated...
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Zacks via Yahoo Finance· 5 days agoNovavax (NVAX) closed the most recent trading day at $14.06, moving +1.99% from the previous trading...
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Zacks· 6 days agoFree Report) closed the most recent trading day at $14.06, moving +1.99% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.25% for the day. Heading ...
A Synergy Of Excellence: Novavax-Mabion Partnership During Unprecedented Times Amid The Covid-19...
BioresearchOnline· 6 days agoNovavax's COVID-19 vaccine, Nuvaxovid, was developed in record time with the support of Mabion, a...
The ‘new normal’ for Covid — and tropical diseases
Politico· 5 hours agoPaul Offit, a Children’s Hospital of Philadelphia vaccine expert and an FDA panel member, said he worries that approach could dampen the view of Novavax’s Covid shot, which ...
Summer COVID bump intensifies in L.A. and California, fueled by FLiRT variants
LA Times via AOL· 1 day agoThe new COVID FLiRT subvariants are continuing to increase their dominance, fueling a rise in Los...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 5 days agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
COVID is bouncing back this summer. Here’s what to know
Los Angeles Times· 7 hours agoSummer just started, but California’s not-too-surprising seasonal COVID bump is already going...
FDA advises vaccine manufacturers to make COVID-19 booster targeting KP.2 strain
ABC Action News Tampa Bay· 1 day agoThe FDA has issued an updated recommendation for the fall COVID-19 vaccine formula. "Coverage in the...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...